comprehensive -WSS

comprehensive

author：entertainment 2025-09-28 02:30:49 - browse：89126

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Thursday released a new accounting of artificial intelligence tools cleared for use in health care, adding scores of new products designed to reshape care in several areas of medicine.

The update included 171 new products that use artificial intelligence and machine learning, including 155 authorized since August of 2022. The agency’s data indicate that, after a lull during the Covid-19 pandemic, the number of authorized devices in 2023 is expected to increase by more than 30% over the prior year.

The list of AI devices was first published after a STAT investigation reported that the FDA had failed to keep the public informed on its regulation of AI devices, or crucial details on the tests undertaken to prove their safety and effectiveness. The summary documents that describe new AI devices often fail to break out the demographics of the patients they were tested on, or where the testing took place, which makes it difficult for clinicians and patients to understand their potential biases and weaknesses.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： In shift, Texas to cover initial consult for Afghan baby's gene therapy

focus

WSS

Eye stem cell transplant could help restore vision in injured people

Eye stem cell transplant could help restore vision in injured people

New details revealed about Purdue's marketing of OxyContin

Hospital chaplains balance Covid safety with patients’ spiritual needs

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Majority of Americans think Trump's Ga. election interference case is serious: POLL

Wikipedia

comprehensive

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Ukraine taking heavy casualties 10 weeks into its counteroffensive

Novavax promises a turnaround & Lilly roils the obesity market

Medicare Advantage coverage denials need scrutiny, senators say

After affirmative action ruling, medical educators look to 'holistic review'

Medicare Advantage coverage denials need scrutiny, senators say

United colonoscopy coverage change 'may cost lives,' doctors say

Male doctors called my cancer incurable. A female doctor showed it wasn't

focus

ProMED sees offers of support, but its future remains unclear

Cancer drug shortages' outsize impact on ovarian cancer patients

Nonprofit, backed by Microsoft, to certify AI tools in health care

STAT Virtual Event: JPM Recap, Live!

An interview with Robert F. Kennedy Jr. on vaccines

In shift, Texas to cover initial consult for Afghan baby's gene therapy

focus

focus

hotspot

Wikipedia